Injection therapy for chronic prostatitis: A retrospective analysis of 77 cases


Submitted: October 14, 2017
Accepted: December 17, 2017
Published: March 31, 2018
Abstract Views: 2302
PDF: 4903
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Attila Toth The MacLeod Laboratory, Weill-Cornell Medical College, New York Presbyterian Hospital, New York, United States.
  • Frederico Maria Guercini The MacLeod Laboratory, Weill-Cornell Medical College, New York Presbyterian Hospital, New York, United States.
  • Dawn Marta Feldthouse The MacLeod Laboratory, Weill-Cornell Medical College, New York Presbyterian Hospital, New York, United States.
  • Jun Chao Zhang The MacLeod Laboratory, Weill-Cornell Medical College, New York Presbyterian Hospital, New York, United States.
Objective: To compare pre- and post-therapy symptom scores reported on the National Institute of Health Chronic Prostatitis Symptom Index (NIHCPSI) after trans-rectal antibiotic injections therapy for men suffering from chronic prostatitis.
Materials and methods: Retrospective analysis of NIHCPSI symptom scores obtained from chart reviews of 77 treated males suffering from chronic prostatitis before and after trans rectal injections for the treatment of chronic prostatitis.
Results: Most patients reported a 40% to 60% improvement in symptom scores. In subgroups comparing scores in patients with less than 5 injections, the improvement was less than in patients who received 10 or more injections. Patients’ responses after a shorter (3 months) follow up showed better pain scores than patient’s scores after longer, over one-year or more, follow- up periods.
Conclusion: Our findings show that direct antibiotic injection for chronic prostatitis is a viable addition to standard therapies. Improvements in symptom scores are long lasting. Discomfort is minimal and side effects are rare and avoidable

Supporting Agencies

The MacLeod Laboratory, New York Office, 65 East 79th Street, New York, NY. 1007

Toth, A., Guercini, F. M., Feldthouse, D. M., & Zhang, J. C. (2018). Injection therapy for chronic prostatitis: A retrospective analysis of 77 cases. Archivio Italiano Di Urologia E Andrologia, 90(1), 34–39. https://doi.org/10.4081/aiua.2018.1.34

Downloads

Download data is not yet available.

Citations